Drug Insights

Is Finerenone approved by the FDA?

16 July 2024
2 min read

Yes, finerenone (Kerendia) is FDA approved. The U.S. Food and Drug Administration (FDA) approved finerenone on July 9, 2021. This approval is based on its efficacy in reducing the risk of kidney function decline, cardiovascular events, and heart failure hospitalizations in patients with CKD associated with type 2 diabetes.

Uses and Benefits

Finerenone is used to reduce the risk of:

  • Worsening kidney problems
  • Heart attacks
  • Hospitalization for heart failure
  • Death from heart failure

Administration and Dosage

Finerenone is available in oral tablet form, typically prescribed in doses of 10 mg or 20 mg. It can be taken with or without food. For patients with an estimated glomerular filtration rate (eGFR) of at least 60 mL/min/1.73 m², the usual starting dose is 20 mg once a day. For those with an eGFR of 25 to less than 60 mL/min/1.73 m², the starting dose is 10 mg once a day, with a target dose of 20 mg daily.

Side Effects

Common side effects of finerenone include:

  • High potassium levels (hyperkalemia)
  • Low sodium levels (hyponatremia)
  • Low blood pressure (hypotension)

Serious side effects requiring immediate medical attention include:

  • Allergic reactions (hives, difficulty breathing, swelling of face, lips, tongue, or throat)
  • Symptoms of high blood potassium (nausea, weakness, tingling, chest pain, irregular heartbeats)
  • Symptoms of low blood sodium (headache, confusion, memory problems, weakness, unsteady feeling)

Warnings and Precautions

Finerenone should not be used by individuals who are allergic to it or have adrenal gland issues. Patients should inform their doctor about all other medications they are taking, as certain drugs should not be used with finerenone due to potential interactions. Additionally, it is important to avoid grapefruit products while taking finerenone, as grapefruit can interact with the medication and cause side effects.

Conclusion

Finerenone is an FDA-approved medication effective in managing chronic kidney disease associated with type 2 diabetes, reducing risks of kidney and cardiovascular complications. It is essential to use this medication under medical supervision due to its potential side effects and interactions with other drugs.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

MEKanistic Therapeutics Inc.'s MTX-531 Shows Tolerability and Tumor Reduction in Preclinical Studies
Latest Hotspot
3 min read
MEKanistic Therapeutics Inc.'s MTX-531 Shows Tolerability and Tumor Reduction in Preclinical Studies
16 July 2024
MEKanistic Therapeutics Inc.’s innovative dual-target therapy, MTX-531, shows considerable tolerability and sustained tumor reduction in preclinical cancer studies.
Read →
Is Aducanumab approved by the FDA?
Drug Insights
2 min read
Is Aducanumab approved by the FDA?
15 July 2024
Aducanumab, sold under the brand name Aduhelm, is an intravenous medication used to treat Alzheimer's disease. Aducanumab was approved by the U.S. Food and Drug Administration (FDA) on June 7, 2021.
Read →
FDA Approves Rgenta Therapeutics' IND for RGT-61159, an Oral RNA Modulator Targeting ACC and CRC
Latest Hotspot
3 min read
FDA Approves Rgenta Therapeutics' IND for RGT-61159, an Oral RNA Modulator Targeting ACC and CRC
15 July 2024
Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).
Read →
Is Ryplazim approved by the FDA?
Drug Insights
2 min read
Is Ryplazim approved by the FDA?
15 July 2024
Ryplazim was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021. This approval marked a significant milestone as Ryplazim is the first therapy approved for treating plasminogen deficiency type 1.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.